Hydrazine (antidepressant)

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Iproniazid, the first hydrazine MAOI to be discovered.

The hydrazine antidepressants are a group of non-selective, irreversible monoamine oxidase inhibitors (MAOIs) which were discovered and initially marketed in the 1950s and 1960s. Most have been withdrawn due to toxicity, namely hepatotoxicity, but a few still remain in clinical use.

Tranylcypromine, a structurally unrelated MAOI introduced around the same time as the hydrazines, was originally advertised as non-hydrazine as a result of its diminished propensity for causing hepatotoxicity.

List of hydrazine antidepressants

Marketed

Benmoxin (Neuralex, Nerusil) ^‡
Iproclozide (Sursum) ^‡
Iproniazid (Marsilid) ^‡
Isocarboxazid (Marplan)
Mebanazine (Actomol) ^‡
Nialamide (Niamid) ^‡
Octamoxin (Ximaol, Nimaol) ^‡
Phenelzine (Nardil)
Pheniprazine (Catron) ^‡
Phenoxypropazine (Drazine) ^‡
Pivhydrazine (Tersavid) ^‡
Safrazine (Safra) ^‡

Legend: ^‡ = Withdrawn from the market; ^† = Partially discontinued; Bolded names indicate major drugs.

Never marketed

Parkinson's

Carbidopa

Tranquillosedative

Centazolone

References

López-Muñoz F, Alamo C (2009). "Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today". Current Pharmaceutical Design. 15 (14): 1563–86. doi:10.2174/138161209788168001. PMID 19442174. Archived from the original on 2013-04-14.{{cite journal}}: CS1 maint: unfit URL (link)